Navigation Links
GeneGo Announces Integration With GenomeQuest for Pathway Analysis of Next Generation Sequencing Data
Date:10/7/2010

ST JOSEPH, Mich., Oct. 7 /PRNewswire/ -- GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, announced today that they have integrated GenomeQuest's Sequence Data Management (SDM) platform with GeneGo's MetaCore and MetaDrug.

Using GenomeQuest's interactive analysis, scientists who have drilled down to a list of particular genes of interest (hundreds of millions of reads, to thousands of expressed genes, to dozens or more of particular genes of interest) can now seamlessly pass that gene list along with their associated expression values (RPKM) to the GeneGo suite of pathway analysis software tools.

"The ability to analyze hundreds of datasets, reducing millions of reads down to a shorter list of particular genes of interest, and then being able to visualize where those genes are active in specific (potentially disease-related) pathways, is a significant accomplishment in the integration of omics software offerings.  Scientists will be able to quickly focus on their scientific questions, rather than manipulating large reads datasets and lists of thousands of genes.  We believe this will enhance discovery throughout the genomics and proteomics research pipelines," said Dr. Don Gregory, GenomeQuest's Director of Field Application Scientists.  

"This integration will allow our joint customers to seamlessly work with NGS data in the context of pathways," said Julie Bryant, VP of business development for GeneGo.  "The integrated workflows will lead our users from raw sequence runs to functional hypothesis generation of drug targets and biomarkers. With NGS data picking up steam in translational medicine and individual healthcare, this integration will help us to leverage our unique disease pathology maps (causal models) developed in our MetaMiner programs in oncology, CNS, metabolic, respiratory diseases and other therapeutic areas."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscoveryplatform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.3, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.3 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About GenomeQuest

GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. Over 160 leading health and agriculture companies use GenomeQuest for mission-critical work, including nine of the top ten pharmaceuticals. The company's core technology is the GQ-Engine -- a database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale.

For more information, please visit the company's web site at www.genomequest.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
2. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
3. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
4. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. University of Glasgow Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
7. Queensland Facility for Advanced Bioinformatics (QFAB) Becomes a GeneGo Center of Excellence for the Asia Pacific Region
8. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
9. GeneGo Announces Systems Tox Relationship With Entelos
10. Childrens Memorial Research Center, Chicago Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program
11. Cardiff University Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Maryland (PRWEB) , ... December ... ... announces the commercial launch of flexible packaging for their exceptionally efficient ... disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered to ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. ... and expansion clinical trial for its lead drug candidate, AC0010, at the World ... trial was to determine the safety, antitumor activity, and recommended phase II dosage ...
(Date:12/7/2016)... Corp. ("Zenith" or the "Company") announces webcast details for a ... and Special Meeting. The Zenith Annual and ... 15, 2016 at Mount Royal University, ... Gate SW, Calgary, Alberta , commencing at ... circular, containing the matters to be considered at the meeting, ...
Breaking Biology Technology:
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
(Date:12/6/2016)... 2016 Valencell , the leading innovator ... seen a third consecutive year of triple digit growth ... 2016 with a 360 percent increase in companies who ... was driven by sales of its wrist and ear ... its technology for hearables for fitness and healthcare applications. ...
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
Breaking Biology News(10 mins):